ConductScience.org, home

Paper16636248

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

Pope WB and 4 others. Neurology, 2006. Cited by 230 papers, by iCite.

Cite this record

ConductScience Library. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Papers, record 16636248. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16636248

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.
PubMed
Journal
Neurology
PubMed
Year
2006
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
230
iCite
Relative citation ratio, by iCite
5.63
iCite
Revised in PubMed
2022-03-30
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pope WBW B
2Lai AA
3Nghiemphu PP
4Mischel PP
5Cloughesy TFT F

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
GliomaMajor topic
Adult
Aged
Antibodies, Monoclonal, Humanized
Bevacizumab
Camptothecin
Carboplatin
Drug Therapy, Combination
Etoposide
Female
Humans
Irinotecan
Magnetic Resonance Imaging
Male
Middle Aged
Neoplasm Recurrence, Local
Vascular Endothelial Growth Factor A

Source PubMed

Download CSV of topics

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in17159134MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.https://conductscience.org/library/papers/17159134

Source PubMed

Download CSV of comments and corrections

Cited by129

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 230 citations.

PMIDTitleJournalYearIn PapersSource
42199889Case Report: Beyond two years: a neurosurgical review of prolonged survival and late recurrence in IDH-wildtype GBM.Front Surg2026https://conductscience.org/library/papers/42199889PubMed
39330753Magnetic Resonance-Guided Cancer Therapy Radiomics and Machine Learning Models for Response Prediction.Tomography2024https://conductscience.org/library/papers/39330753PubMed
39162874Is add-on Bevacizumab therapy to Temozolomide and radiotherapy associated with clinical utility for newly diagnosed Glioblastoma? A systematic review and meta-analysis.Neurosurg Rev2024https://conductscience.org/library/papers/39162874PubMed
38596714Antiangiogenic exclusion rules in glioma trials: Historical perspectives and guidance for future trial design.Neurooncol Adv2024https://conductscience.org/library/papers/38596714PubMed
38406805First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study.Front Oncol2024https://conductscience.org/library/papers/38406805PubMed
35419519The impact of different volumetric thresholds to determine progressive disease in patients with recurrent glioblastoma treated with bevacizumab.Neurooncol Adv2022https://conductscience.org/library/papers/35419519PubMed
34047805Longitudinal structural and perfusion MRI enhanced by machine learning outperforms standalone modalities and radiological expertise in high-grade glioma surveillance.Neuroradiology2021https://conductscience.org/library/papers/34047805PubMed
33828976Seizures, Edema, Thrombosis, and Hemorrhages: An Update Review on the Medical Management of Gliomas.Front Oncol2021https://conductscience.org/library/papers/33828976PubMed
32957732Aptamer-Based In Vivo Therapeutic Targeting of Glioblastoma.Molecules2020https://conductscience.org/library/papers/32957732PubMed
32524791Radiological Recurrence Patterns after Bevacizumab Treatment of Recurrent High-Grade Glioma: A Systematic Review and Meta-Analysis.Korean J Radiol2020https://conductscience.org/library/papers/32524791PubMed
32152825Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma.Mol Neurobiol2020https://conductscience.org/library/papers/32152825PubMed
32076934Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: where are we now, and where we are going.J Neurooncol2020https://conductscience.org/library/papers/32076934PubMed
31689995Progression-Free but No Overall Survival Benefit for Adult Patients with Bevacizumab Therapy for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis.Cancers (Basel)2019https://conductscience.org/library/papers/31689995PubMed
29779086Retrospective study of nivolumab for patients with recurrent high grade gliomas.J Neurooncol2018https://conductscience.org/library/papers/29779086PubMed
29660005Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.Neuro Oncol2018https://conductscience.org/library/papers/29660005PubMed
29622553Edge Contrast of the FLAIR Hyperintense Region Predicts Survival in Patients with High-Grade Gliomas following Treatment with Bevacizumab.AJNR Am J Neuroradiol2018https://conductscience.org/library/papers/29622553PubMed
29040703Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma.Neuro Oncol2018https://conductscience.org/library/papers/29040703PubMed
28927109Disease progression patterns of bevacizumab responders with recurrent malignant gliomas.Oncol Lett2017https://conductscience.org/library/papers/28927109PubMed
28819189Vascular Hysteresis Loops and Vascular Architecture Mapping in Patients with Glioblastoma treated with Antiangiogenic Therapy.Sci Rep2017https://conductscience.org/library/papers/28819189PubMed
28516072Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications.Brain Tumor Res Treat2017https://conductscience.org/library/papers/28516072PubMed

See all 129 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/16636248

GET https://conductscience.org/api/papers/v1/16636248/cited_by?page=2